Carpal Tunnel Syndrome - Randomized Clinical Trial Evaluating Effectiveness of Ultrasound in Corticosteroid Injection
NCT ID: NCT02036125
Last Updated: 2014-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2013-10-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this randomised clinical trial, 50 patients with both a clinical and electromyographic diagnosis of mild to moderate carpal tunnel syndrome will be recruited from the Centre Hospitalier Universitaire de Sherbrooke (CHUS). Subjects will be randomised to ultrasound guided or blind injection groups. All subjects will receive 40 mg of methylprednisolone. The primary outcome will be the Boston Carpal Tunnel Syndrome Questionnaire - Symptom Severity Scale at baseline and 3 months post injection. Both subjects and assessors will be blinded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ultrasound guided injection
Ultrasound guided injection of 40 mg of methylprednisolone
Ultrasound
Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
methylprednisolone
Subjects will receive a blind injection of 40 mg of methylprednisolone.
Blind injection
Blind injection of 40 mg of methylprednisolone
methylprednisolone
Subjects will receive a blind injection of 40 mg of methylprednisolone.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultrasound
Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
methylprednisolone
Subjects will receive a blind injection of 40 mg of methylprednisolone.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Understanding written and spoken french
* Diagnostic of carpal tunnel syndrome : Classic of probable based on the Katz Hand Diagram and mild to moderate based on the electrodiagnosis studies
Exclusion Criteria
* Constant symptoms in medial nerve area
* Thenar eminence atrophy
* Absolute contraindication to corticosteroid injection : infective arthritis, bacterial endocarditis, local cellulitis of skin infection, coagulopathy, corticosteroid or latex allergy
* Secondary diagnosis based on the ultrasound : arthrosynovial cyst, flexor tenosynovitis, ganglion
* Known cognitive disorder
* Anticoagulant therapy
* Diseases known to cause carpal tunnel syndrome : Diabetes mellitus, hypothyroidism, connective tissue disease, rheumatic disease and moderate or severe chronic renal impairment
* Radiculopathy
* Polyneuropathy
* Pregnancy
* Ancient ipsilateral wrist fracture
* Ancient ipsilateral wrist surgery
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université de Sherbrooke
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alessandra Bruns
MD, FRCPC
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alessandra Bruns, Md, FRCPC
Role: PRINCIPAL_INVESTIGATOR
Université de Sherbrooke
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Alessandra Bruns, MD, FRCPC
Role: CONTACT
Phone: 819 564 5261
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Alessandra Bruns, MD, FRCPC
Role: primary
Anne-Marie Pitre-Joyal, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-143
Identifier Type: -
Identifier Source: org_study_id